 |
Case Report
Treatment with chemotherapy plus brentuximab vedotin in anaplastic large cell lymphoma and pregnancy: A case report
1 PharmD., Pharmacist Intern, Clearview Cancer Institute, Huntsville, Alabama, United States
2 PharmD., BCOP, Clinical Oncology Pharmacist, Clearview Cancer Institute, Huntsville, Alabama, United States
3 MSN, RN, OCN, Director of Nursing, Clearview Cancer Institute, Huntsville, Alabama, United States
4 MSN, CRNP, ACNP-BC, Director of Quality and Value Based Care, Clearview Cancer Institute, Huntsville, Alabama, United States
5 MD, Medical Oncologist, Clearview Cancer Institute, Huntsville, Alabama, United States
Address correspondence to:
Emma E Pride
11016 Thorne Drive NW, Madison, Alabama 35757,
United States
Message to Corresponding Author
Article ID: 100136Z10EP2024
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Pride EE, Calahan JP, Shaver SMC, Creel BN, Waples JM. Treatment with chemotherapy plus brentuximab vedotin in anaplastic large cell lymphoma and pregnancy: A case report. J Case Rep Images Oncology 2024;10(2):15–19.ABSTRACT
Introduction: Brentuximab vedotin (BV) is a CD-30 directed antibody and microtubule inhibitor conjugate indicated for the treatment of multiple types of lymphoma, including anaplastic large cell lymphoma (ALCL). Consensus-based guidelines recommend BV with cyclophosphamide, doxorubicin, and prednisone (CHP) as first-line treatment in a patient with ALCL. Alternative treatment options for ALCL can be limited due to patient-specific factors. Lymphomas account for approximately 11% of cancers in pregnancy. Brentuximab vedotin has not been studied in pregnancy; therefore, making the use of an antibody drug conjugate in this patient the first documented use in pregnancy.
Case Report: A 26-year-old female was diagnosed with anaplastic large cell lymphoma at 14 weeks gestation. The patient has a past medical history of ALCL in 2004 at eight years old and a prior miscarriage. Consensus-based guidelines recommend BV with cyclophosphamide, doxorubicin, and prednisone (CHP) as first-line treatment in a patient with ALCL. Treatment with BV plus CHP was initiated at 15 weeks gestation for a total of 6 cycles during the antepartum period. At 33 weeks gestation, the patient delivered a 4-pound infant male without complications, birth defects, or health disparities. Two additional cycles of BV and CHP were administered during the postpartum period. Complete remission has been achieved in this patient.
Conclusion: The outcomes in this case indicate the potential safety of BV in patients after the first trimester of pregnancy.
Keywords: Anaplastic large cell lymphoma in pregnancy, Brentuximab vedotin in pregnancy, Brentuximab vedotin in pregnancy and lymphoma, Pregnancy and lymphoma
SUPPORTING INFORMATION
Author Contributions
Emma E Pride - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Jacob P Calahan - Acquisition of data, Analysis of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Shannon M Collins Shaver - Analysis of data, Revising it critically for important intellectual content, Final approval of the version to be published
Brandi N Creel - Analysis of data, Revising it critically for important intellectual content, Final approval of the version to be published
John M Waples - Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2024 Emma E Pride et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
